Travere Therapeutics(DE:17R)
€33.000.00 (0.00%)
DE:17R
Travere Therapeutics stock drug pipeline
€33.00
At close:0.00 (0.00%)
Travere Therapeutics (17R) Drug Pipeline
2 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sparsentan | Focal Segmental Glomerulosclerosis, Kidney Transplant, Proteinuria, Immunoglobulin A (Iga) Nephropathy | Phase IV | Recruiting | Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | Oct 09, 2025 | ― |
| Pegtibatinase | Homocystinuria | Phase III | Enrolling By Invitation | A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) | May 08, 2024 | ― |
| Pegtibatinase | Homocystinuria | Phase III | Active Not Recruiting | A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment | Jan 30, 2024 | ― |
| Sparsentan | Immunoglobulin A Nephropathy | Phase II | Completed | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN | May 03, 2023 | ― |
| Sparsentan | Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy, Alport Syndrome, Minimal Change Disease, Iga Vasculitis | Phase II | Recruiting | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | Jul 29, 2021 | ― |
| Dapagliflozin, Irbesartan, Sparsentan | Immunoglobulin A Nephropathy | Phase III | Active Not Recruiting | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy | Nov 27, 2018 | ― |
| Irbesartan, Sparsentan | Focal Segmental Glomerulosclerosis | Phase III | Active Not Recruiting | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | Apr 03, 2018 | ― |
| Pegtibatinase | Homocystinuria | phase1AndPhase2 | Active Not Recruiting | Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE) | Dec 05, 2017 | ― |
| Irbesartan, Re-021 (Sparsentan) | Focal Segmental Glomerulosclerosis | Phase II | Completed | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | Jun 04, 2012 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sparsentan | Phase IV | Focal Segmental Glomerulosclerosis, Kidney Transplant, Proteinuria, Immunoglobulin A (Iga) Nephropathy | Recruiting | Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | Oct 09, 2025 | ― |
| Pegtibatinase | Phase III | Homocystinuria | Enrolling By Invitation | A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) | May 08, 2024 | ― |
| Pegtibatinase | Phase III | Homocystinuria | Active Not Recruiting | A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment | Jan 30, 2024 | ― |
| Sparsentan | Phase II | Immunoglobulin A Nephropathy | Completed | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN | May 03, 2023 | ― |
| Sparsentan | Phase II | Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy, Alport Syndrome, Minimal Change Disease, Iga Vasculitis | Recruiting | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | Jul 29, 2021 | ― |
| Dapagliflozin, Irbesartan, Sparsentan | Phase III | Immunoglobulin A Nephropathy | Active Not Recruiting | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy | Nov 27, 2018 | ― |
| Irbesartan, Sparsentan | Phase III | Focal Segmental Glomerulosclerosis | Active Not Recruiting | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | Apr 03, 2018 | ― |
| Pegtibatinase | phase1AndPhase2 | Homocystinuria | Active Not Recruiting | Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE) | Dec 05, 2017 | ― |
| Irbesartan, Re-021 (Sparsentan) | Phase II | Focal Segmental Glomerulosclerosis | Completed | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | Jun 04, 2012 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Travere Therapeutics, Inc. (DE:17R) have in its pipeline
Travere Therapeutics DE:17R is currently developing the following drugs: Sparsentan, Pegtibatinase, Dapagliflozin, Irbesartan, Sparsentan, Irbesartan, Sparsentan, Irbesartan, Re-021 (Sparsentan). These drug candidates are in various stages of clinical development as the company works toward FDA approval.
